CorAlert

Non-invasive real-time hemodynamic monitoring for the management of heart failure (LVEDP)

Heart failure (HF) affects more than 26 million people globally. More than 40% of persons diagnosed with HF will die within 5 years. HF accounts for nearly $30 billion in medical expenses yearly.
A major contributor to HF’s high mortality rate and cost of treatment is the difficulty in assessing the condition of the heart in real-time. Left ventricular end-diastolic pressure (LVEDP), the left ventricle’s filling pressure, is an accepted index to assess the severity of HF. Unfortunately, measuring LVEDP, to date, requires an invasive procedure.

CorAlert has developed an accurate, easy-to-use, noninvasive device for measuring LVEDP in real-time. Our device accurately estimates LVEDP along with other vital hemodynamic indices. The device supplies the physician a comprehensive hemodynamic profile allowing to accurately determine the exact type and severity of heart failure, and along with the cloud application allows for long term trend analysis and prediction of patient prognosis.

Measuring LVEDP using CorAlert’s device is similar to taking a Blood Pressure (BP) reading using a standard digital BP device. The process takes about 3-5 minutes.

CorAlert conducted a clinical trial using an Alpha model of the device (Ziv Medical Center, Israel). The trial compared LVEDP measured in the Cath lab during routine elective catheterization to the LVEDP measured by CorAlert’s device. Correlation coefficient of the 2 measurements was 0.88 with p value <0.0015. CorAlert completed production of its Beta model which has begun a clinical trial in Israel. Company's Keywords: